Hope S. Rugo, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hope S. Rugo, MD

Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, UCSF

Phone: (415) 353-7070 (appts)
Box 1710, UCSF
San Francisco, CA 94143-1710

View on UCSF Profiles

Cancer Center Membership

Program Member » Breast Oncology

Education

Tufts University, BS, 1979, Chemistry
University of Pennsylvania, MD, 1984, Medicine
University of California San Francisco, 1987, Resident, Internal Medicine
University of California San Francisco, 1990, Fellow, Hematology/Oncology
Stanford University, 1988-90, Postdoctoral Fellowship, Microbiology/Immunology
DNAX Institute of Cellular and Molecular Biology, 1989-90, Visiting Scientist, Immunology


Professional Experience

  • 1990-1992
    Clinical Instructor in Medicine (Div. of Hematology/Oncology), University of California, San Francisco
  • 1992-1997
    Assistant Clinical Professor of Medicine (Div. of Hematology/Oncology), University of California, San Francisco
  • 1997-1999
    Associate Clinical Professor of Medicine (Div. of Hematology/Oncology), University of California, San Francisco
  • 1999-2003
    Associate Clinical Professor of Medicine (Div. of Hematology/Oncology), University of California, San Francisco
  • 2003-present
    Clinical Professor of Medicine (Div. of Hematology/Oncology), University of California, San Francisco
  • 2003-present
    Director, Breast Oncology Clinical Trials Program

Honors & Awards

  • College
    Summa Cum Laude, Phi Beta Kappa, Sigma Xi; Victor Prather Prize for Excellence in Scientific Research; Durkee Scholarship for promise and achievement in the field of chemistry; Max Tishler Prize Scholarship for outstanding achievement in the sciences
  • Medical School
    Henry Luce Scholar in the Philippines; Certificate of Commendation, Philadelphia Area Project on Occupational Safety and Health; National Health Service Corps Scholarship; Janet M. Glasgow Memorial Achievement Citation
  • 1990
    Awarded Bank of America Gianini Foundation Research Fellowship

Selected Publications

  • Damon LE, Rugo HS, Ries CA, Linker CA: Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia 1994;8:535-41.
  • Rugo HS, Damon LE, Ries CA, Wolf J, Linker CA. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma, and multiple myeloma. Prog Clin Biol Res 1994;389:505-11.
  • Damon LE, Rugo HS, Ries CA, Linker CA: Delayed engraftment of 4-hydroxyperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transpl 1996;17:93-99.
  • Cunningham ET, Irvine AR, Rugo HS: Bone marrow transplant retinopathy in the absence of radiation therapy. Am J Ophthal 1996;122:268-270.
  • Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA: High-dose Cytarabine Dose Modification Reduces the Incidence of Neurotoxicity in Patients with Renal Insufficiency. J Clin Oncol 1997;15:833-839.
  • Feldman, EJ, Seiter K, Damon L, Linker C, Rugo H, Rise C, Case DC, Beer M, Ahmed T: A Randomized Trial of High- vs Standard-dose Mitoxantrone with Cytarabine in Elderly Patients with Acute Myeloid Leukemia. Leukemia 1997:11:485-489.
  • Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL: Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplantation. 1998, 22: 865-872.
  • Vescio R, Schiller G, Stewart K, Ballester O, Noga S, Rugo H et al: Multicenter Phase III Trial to Evaluate CD 34+ Selected vs. Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma. Blood 1999;93:1-13.
  • Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, et al: Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients. Bone Marrow Transplant 2000;25:153-160.
  • Damon LE, Wolf JL, Rugo HS, Gold E, Ries CA, Zander AR, Tracy M, Cecchi G, Linker CA. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000;26:257-268.
  • Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS, et al: Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2000;6:50-57.
  • Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C: NCCN practice guidelines for cancer-related fatigue. Oncology 2000;14(S10):151-161.
  • Rugo H, Tripathy D: New developments in cancer therapeutics targeting HER2/neu and other growth factor receptors. Biotechnology International 2001:203-212.
  • Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001;8:549-59.
  • Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobc C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high dose chemotherapy for multiple myeloma: results of a multicenter randomized trial. J Clin Oncol 2001;19:3771-9.
  • Rugo HS: Novel therapies for cancer. San Francisco Medicine 2001, 74:16-18.
  • Gordon KB, Rugo HS, Duncan JL et al: Ocular manifestations of leukemia: Leukemic infiltration versus infectious process. Opthalmology 2001;108:2293-300.
  • Rugo H, Ahles T. The Impact of Adjuvant Therapy for Breast Cancer on Cognitive Function: Current Evidence and Directions for Research. Semin Oncol 2003;30:749-62.
  • Rugo H. Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol 2003,4:165-73. Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA.Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA).Arandomized study of etoposide schedule. Cancer Chemother Pharmacol 2004;53:468-74.
  • Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004;9(S1):43-9.
  • Tanchiu E, Kaurman PA, Paik S, Ulcickas-Yood M, mayer M, Tripathy D, Rugo H, Brufsky A. registHER: a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:670.
  • Traina TA, Dickler MN, Caravelli JF, Yeh BM, Brogi E, Panageas K, Flores SA, Norton L, Hudis C, Rugo H. A feasibility study of an aromatase inhinitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2005; 23:796
  • Rugo HS, Dickler MN, Scott JH, Moore DH, Melisko M, Yeh BM, Caravelli J, Brogi E, Hudis C, Park JW. Change in circulating endothelial cells (CEC) and tumor cells(CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation. Proc Am Soc Clin Oncol 2005; 23:525.(oral presentation)
  • Miller KD, Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Pegram MD, Eisenberg PD, Collier M, Adams BJ, Baum CM. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2005; 23:563.
  • Rugo H, Dickler M, Traina T, Scott J, Moore D, Bruckner J, Hudis C, Park J. Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B). Proc Am Soc Clin Oncol 2006;24:3039.
  • Traina T, Rugo H, Caravelli J, Yeh B, Panageas K, Bruckner J, Norton L, Park J, Hudis C, Dickler M. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006; 24:3050.
  • Melisko M, Millerick C, Maniar P, Moore D, Rosenwein M, Rugo H, Esserman L.Impact of taxanes on weight gain during neoadjuvant chemotherapy (Ctx) for breast cancer (BC). Proc Am Soc Clin Oncol 2006;24:10606.
  • Kaufman P, Mayer M, Paik S, Ulcickas Yood M, Yardley D, Tan-Chiu E, Brufsky A, Rugo H, Tripathy D, Wang L. registHER: Baseline characteristics of a cohort of HER2-positive metastatic breast cancer (MBC) patients. Proc Am Soc Clin Oncol 2006; 24:20095.
  • Partridge A, Wolff A, Marcom P, Kaufman P, Moore C, Lake D, Fleming G, Rugo H, Collyar D, Winer E. Study participants' perceptions of the process and impact of receiving results of N9831. Proc Am Soc Clin Oncol 2006; 24:518.
  • Damon L, Rugo H, Tolaney S, Navarro W, Martin T 3rd, Ries C, Case D, Ault K, Linker C. Cytoreduction of Lymphoid Malignancies and Mobilization of Blood Hematopoietic Progenitor Cells with High Doses of Cyclophosphamide and Etoposide Plus Filgrastim Biol Blood Marrow Transplant. 2006, 12:316-24.
  • Rugo HS, Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with Cyclin D1 amplification (Literature Review) New Directions in Endocrine Treatment of Breast Cancer 2006, 1:10.
  • Rugo HS, Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen In postmenopausal women with advanced breast cancer (Literature Review) New Directions in Endocrine Treatment of Breast Cancer 2006, 1:14.
  • Rugo HS, Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in Premenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)- The German Adjuvant Breast Cancer Group (Literature Review) New Directions in Endocrine Treatment of Breast Cancer 2006,1:15.